𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A multicenter phase II study

✍ Scribed by Cornelis J. A. Punt; Jos Th. M. Burghouts; Jelle J. Croles; Peter A. van Liessum; Pieter H. M. de Mulder; Yvonne Kamm

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
499 KB
Volume
72
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II trial of weekly high dose con
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer
✍ Enrique Aranda; AndrΓ©s Cervantes; Javier Dorta; Esperanza Blanco; Carlos FernΓ‘nd πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 419 KB πŸ‘ 1 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

Bimonthly high dose leucovorin and 5-flu
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma
✍ Christophe Tournigand; Christophe Louvet; Aimery de Gramont; Elisabeth Lucchi; J πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 88 KB πŸ‘ 1 views

disease progression. IFN was administered subcutaneously three times weekly at for the Groupe d'Etude et de a dose of 3 MU (body surface area [BSA] Γ΅ 1.75 m 2 ) or 4.5 MU (BSA Β’ 1.75 m 2 ). Recherche sur les Cancers de RESULTS. World Health Organization toxicity Grade 3-4 occurred in 21 patients l'O